[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer]

Area of Science:

• Oncology
• Clinical Medicine
• Pharmacology

Background:

• The last decade has seen significant progress in non-small cell lung cancer (NSCLC) clinical management.
• Introduction of pemetrexed and targeted therapies (bevacizumab, erlotinib, gefitinib) has impacted first and second-line treatments.
• Novel maintenance strategies for NSCLC and non-squamous NSCLC have emerged, improving patient survival.

Purpose of the Study:

• To summarize recent changes in the diagnosis and therapy of non-small cell lung cancer (NSCLC).
• To present the updated therapeutic scheme for NSCLC management.
• To highlight the impact of new drugs and molecular markers on NSCLC treatment.

Main Methods:

• Review of clinical advancements in NSCLC management over the past decade.
• Analysis of the introduction and efficacy of pemetrexed and targeted therapies.
• Examination of novel maintenance therapeutic strategies and their impact on survival.

Main Results:

• Pemetrexed and targeted therapies (bevacizumab, erlotinib, gefitinib) are now integral to NSCLC treatment.
• Maintenance therapies like erlotinib and pemetrexed+bevacizumab have significantly improved patient survival.
• Refined differential diagnosis and molecular predictive markers underpin these therapeutic advances.

Conclusions:

• Clinical management of NSCLC has been substantially improved by new therapies and diagnostic refinements.
• Updated guidelines and reimbursement schemes are necessary due to drug registration changes.
• The evolving landscape of NSCLC treatment necessitates continuous adaptation of therapeutic strategies.